Last Price$81.21NASDAQ Previous Close - Last Trade as of 4:00PM ET 9/20/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$79.64 (1)
Ask (Size)$81.70 (1)
Day Low / HighN/A - N/A
Volume2.2 M

View Biotechnology IndustryPeer Comparison as of 09/20/2019


Incyte Corp ( NASDAQ )

Price: $81.21
Change: +3.09 (3.96%)
Volume: 2.2 M
4:00PM ET 9/20/2019

Exact Sciences Corp ( NASDAQ )

Price: $103.97
Change: +0.57 (0.55%)
Volume: 3.6 M
3:59PM ET 9/20/2019

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $74.95
Change: -1.05 (1.38%)
Volume: 1.7 M
4:00PM ET 9/20/2019

Seattle Genetics Inc ( NASDAQ )

Price: $74.01
Change: +1.23 (1.69%)
Volume: 1.5 M
3:59PM ET 9/20/2019

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $106.32
Change: +0.65 (0.62%)
Volume: 2.6 M
4:00PM ET 9/20/2019

Read more news Recent News

US Stocks Push Higher, Buttressed by Energy Gains as Traders Digest Rosengren Comments
11:08AM ET 9/20/2019 MT Newswires

US equity benchmarks were modestly higher on the final trading day of the week, supported by strong gains in the energy and health care sectors which were...

Analyst Actions: BMO Capital Starts Incyte at Market Perform With $85 Price Target
10:56AM ET 9/12/2019 MT Newswires

Incyte (INCY) has an average rating among analysts of buy, with an average price target of $92. Price: 76.69, Change: -1.79, Percent Change: -2.28 ...

Consensus Q3, 2019, 2020 Estimates for Incyte Scaled Up
12:46AM ET 9/06/2019 MT Newswires

Q3, 2019, and 2020`s earnings projections for Incyte Corp (NASDAQ:INCY, Recent Price: 79.27) have been revised upward. The Q3 earnings estimate has been...

--Analyst Actions: Oppenheimer Upgrades Incyte to Outperform From Perform, Lifts PT to $100 From $85
12:20PM ET 9/05/2019 MT Newswires

Price: 78.96, Change: +1.33, Percent Change: +1.72 ...

Company Profile

Business DescriptionIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. View company web site for more details
Address1801 Augustine Cut-Off
Wilmington, Delaware 19803
Number of Employees1,367
Recent SEC Filing09/19/20194
Chairman, President & Chief Executive OfficerHervé Hoppenot
Chief Financial Officer & Executive Vice PresidentChristiana Stamoulis
Chief Medical Officer & Executive Vice PresidentSteven H. Stein
Chief Scientific Officer & Executive VPDashyant Dhanak

Company Highlights

Price Open$78.52
Previous Close$78.12
52 Week Range$57.00 - 89.30
Market Capitalization$17.5 B
Shares Outstanding215.1 M
SectorHealth Technology
Next Earnings Announcement10/29/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings57.60
Earnings per Share$1.54
Beta vs. S&P 500N/A
Revenue$1.9 B
Net Profit Margin15.25%
Return on Equity15.18%

Analyst Ratings as of 09/10/2019

Consensus RecommendationConsensus Icon
Powered by Factset